Prilosec OTC impacting Protonix?
This article was originally published in The Tan Sheet
Executive Summary
Wyeth reiterates Procter & Gamble's recent launch of Prilosec OTC (omeprazole) will not impact sales of its Rx GERD treatment Protonix (pantoprazole sodium) (1"The Tan Sheet" July 28, 2003, p. 11). During Bear Stearns Healthcare Conference in New York City Sept. 9, Wyeth North America President Joseph Mahady notes "the change in market status from a single omeprazole generic to now having multiple generics...will more than likely have the most significant change on the market. In our opinion that will be more critical to the performance of Protonix in the future than will be the availability of an OTC version of Prilosec"...
You may also be interested in...
Alavert Sales Up 48% As Wyeth Stands Strong In Crowded Loratadine Market
Wyeth is confident that its Alavert loratadine product will weather the launch of several private label and generic rivals and build on the brand's strong second quarter sales performance
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.